Bacterial DNA induces a proinflammatory immune response in patients with decompensated cirrhosis

We read with interest the study of Thalheimer et al (Gut 2005;54:556–63) in which they reviewed actual knowledge regarding the influence of infection on haemodynamics, variceal haemorrhage, hepaticorenal effects, liver damage, and other effects. We agree with these assumptions and would like to add information not quoted in the paper that may help explain some of the immune abnormalities usually found in patients with advanced decompensated cirrhosis. As the authors detailed in their paper, our group has reported on the detection of bacterial DNA in a significant proportion of patients with cirrhosis and culture-negative bacteraemia, and nitric oxide levels are higher than those in culture-negative patients. In part, the induced ability to secrete nitric oxide than cells in culture also displayed a significantly increased ability to secrete this type of nitric oxide, and similar molecules, as demonstrated in patients with advanced cirrhosis.

J Such
Liver Unit, Hospital General Universitario, Pintor Baeza s/n, Alicante, Spain

C Muñoz
Department of Immunology, Hospital General Universitario, Pintor Baeza s/n, Alicante, Spain

P Zapater
Department of Clinical Pharmacology, Hospital General Universitario, Pintor Baeza s/n, Alicante, Spain

M Pérez-Mateo
Liver Unit, Hospital General Universitario, Pintor Baeza s/n, Alicante, Spain

Correspondence to: Dr J Such, Liver Unit, Hospital General Universitario, Pintor Baeza s/n, Alicante, Spain; such_j@gsa.es

Conflict of interest: None declared.

References

Author’s reply
We are grateful to Such et al for their comments on our review. As we had outlined, the influence of bacterial infection on the pathophysiology of cirrhosis is indeed an important one and Such et al have contributed significantly to this topic.† We were aware of their data, but unfortunately some of it could not be retained in the final version of our paper due to editorial restrictions. Nevertheless, we agree that the presence of bacterial DNA, in the absence of viable bacteria or endotoxaemia, might be an additional step in the sequence of events outlined in fig 2 of our review, even preliminary to endotoxaemia.

U Thalheimer, C K Triantos, D N Samonakis, D Patch, A K Burroughs
Liver Transplant and Hepatobiliary Medicine, Royal Free Hospital, London, UK

Correspondence to: Professor A K Burroughs, Liver Transplant and Hepatobiliary Medicine, Royal Free Hospital, Hampstead, London NW3 2QG, UK; andrew.burroughs@royalfree.nhs.uk

Conflict of interest: None declared.

Perinatal passive smoke exposure may be more important than childhood exposure in the risk of developing childhood IBD

The large case control study of patients with inflammatory bowel disease (IBD) in the French paediatric population by Barón et al has clarified the role of well established genetic and environmental risk factors, as well as suggesting novel environmental risk factors (Gut 2005;54:357–63). However, we caution the authors on dismissal of the role of passive smoking in the risk of IBD development in childhood. Our own data would suggest that analysing smoking data during pregnancy and at birth is more important in the development of childhood IBD, rather than assessing smoking during childhood and at disease onset, as performed in this current study.

We have performed a case control study in South East Scotland of children with early onset IBD, matching cases of IBD diagnosed at less than 16 years of age with same sex and age (±1 year) controls attending the same general practice. In total, we matched 62 pairs of cases and controls, with a median age of disease onset in cases of 10.6 years. We demonstrated that parental smoking during pregnancy and around the time of birth was more common in parents of IBD cases, at 54% compared with controls at 29% (p = 0.01; odds ratio (OR) 2.87 (95% confidence interval (CI) 1.23–6.66)). Maternal smoking during pregnancy and at birth was also more common in IBD cases than in controls, at 23% versus 6.2% (p = 0.04; OR 4.46 (95% CI 1.16–17.1)). In mothers of patients with Crohn’s disease, at 27.8% versus control mothers at 8.3% (p = 0.03; OR 4.23 (95% CI 1.05–16.97)). There was no significant effect seen when paternal smoking in pregnancy and at birth was analysed in IBD cases versus controls (p = 0.27). These
data replicate the publication by Lashner and colleagues who studied 72 IBD cases and controls and found a similar relationship to smoking at birth—this was increased in children who later developed IBD in childhood (OR 3.02) and CD in childhood (OR 5.32). The authors of this study also demonstrated that maternal smoking at birth was important in the development of IBD and CD.

We agree with the findings of Baron et al that parental/passive smoke exposure outside of the perinatal period, including at the time of pregnancy and at birth with the risk of having a child with IBD. When assessing passive smoking in children who later developed IBD, we found a similar relationship to parental smoking at birth with the risk of childhood IBD. When assessing passive smoking in children who later developed IBD in childhood (p = 0.18). This lack of association between passive smoke exposure in childhood and development of childhood IBD has also been replicated by Lashner and colleagues.

It is important to note that the other studies quoted by Baron et al in relation to the risk of passive smoking in IBD patients relate to the risk of adult onset IBD after passive smoke exposure during childhood, not the risk of developing IBD as a child. The mechanism by which smoke exposure during pregnancy and at birth leads to an increased risk of childhood IBD can only be a subject for speculation, but it is interesting to note a recent study that has demonstrated chromosomal abnormalities in fetal epithelial cells in women who smoke during pregnancy.

In conclusion, our study agrees with previously published data to suggest a role between passive smoke exposure during pregnancy and at birth with the risk of childhood development of IBD. When assessing passive smoking in relation to childhood onset IBD, investigators should survey smoke exposure in the perinatal period and during childhood.

R K Russell, R Farhadi, M Wilson, H Drummond, J Satsangi, D C Wilson Gastrointestinal Unit and Department of Child Life and Health, University of Edinburgh, Edinburgh, UK

Correspondence to: Dr R K Russell, Gastrointestinal Unit, University of Edinburgh, Department of Medical Sciences, Edinburgh EH2 2UL, UK; richarrussell77@hotmail.com

Conflict of interest: None declared.

An alternative to prophylactic colectomy for colon cancer prevention in HNPCC syndrome

The surgical option for treatment of a patient with screen detected colorectal cancer (CRC) from a family with hereditary non-polyposis colorectal cancer (HNPCC) is subtotal colectomy or segmental resection. Using decision analysis, we showed that subtotal colectomy performed at a young age leads to an increased life expectancy (LE) of 1–2 years. Based on these results and the high risk of developing a second CRC, we concluded that if CRC is detected in a young patient participating in a surveillance programme, colectomy with ileorectal anastomosis seems to be the treatment of choice.

A French Committee on HNPCC commented on our study. Firstly, they stated that using quality adjusted LE would be a more appropriate approach to childhood CRC, but since the analysis was performed under limited information, the study on quality of life (QOL) did not specifically consider HNPCC patients. In HNPCC, QOL after segmental resection may be decreased by the need for colonoscopy (versus rectoscopy after colectomy) and the fear of a second tumour. Secondly, the committee considered our five year survival rates optimistic. The five year survival rates for HNPCC patients with Dukes’ B cancer varied in the literature from 70% to 91% and those for patients with Dukes’ C from 19% to 70%.

These survival rates are lower than those used in our analysis. Thirdly, the committee mentioned that the overall five year survival of patients with CRC in HNPCC is approximately 55%. They stated that if the decision for an extended resection is made before the pathologic staging of the tumour is known, 45% of patients will sustain a substantial decrease in QOL with no counter-part in quantity (that is, LE). The committee referred to the survival (55%) of symptomatic CRC in HNPCC. In our study, we discussed the surgical options for patients with CRC detected during surveillance. In our table, we showed the stage distribution of screen detected CRC based on our study and the Finnish series. As 86% had local cancer, the five year survival will be higher than 55%. Fourthly, the committee indicated that only a very small proportion of patients will be identified with CRC by the age of 27 years and that the increased LE for patients with CRC diagnosed at age 47 years was only one year. Half of the patients with CRC will be diagnosed before the age of 50 years and will have a substantial increase of LE of 1–2.3 years. Fifthly, the committee stressed that different indications should be made in men and women because of their different risks for metachronous cancer as well as for the competing risk of endometrial cancer. Although female mutation carriers may have a lower risk of CRC than male carriers, it has not been shown that they also have a lower risk of a second CRC. In fact, among HNPCC patients that developed a second tumour, we found more females than males. Female mutation carriers do indeed have a high risk of developing endometrial cancer but this cancer is only a rare cause of death in HNPCC.

As stated by the committee, difficulties could arise for a patient diagnosed with CRC to decide between an increase in LE and a potential decrease in their QOL. An increased LE is a somewhat theoretical concept that entails additional CRC at the end of one’s life. Although the negative impact on QOL of subtotal colectomy will start from the first post-operative day. On the other hand, it may be even more difficult for a physician to explain to a patient that has developed CRC under surveillance that after segmental resection, surveillance of the remaining colon will prevent cancer development. It is possible that this patient will be happy after removal of the colon as now they are at a substantially lower risk of developing a second CRC. We agree that the patient’s choice is pivotal in decisions on prophylactic surgery, after being fully informed of the pros and cons of the surgical options.

H F A Vasen

The Netherlands Foundation for the Detection of Hereditary Tumours, Leiden, the Netherlands

H De Vos tot Nederveen Cappel

Department of Gastroenterology, Leiden University Medical Centre, Leiden, the Netherlands

Correspondence to: Dr H F A Vasen, The Netherlands Foundation for the Detection of Hereditary Tumours, Rijnsburgerweg 10, 2333 AA, Leiden, the Netherlands; hfa@vasen@wxs.nl
doi: 10.1136/gut.2005.075820

Conflict of interest: None declared.
There is however a far easier and well validated method available for the study of human tissue. This is the so-called microdissection technique in which small pieces of stained material are teased apart and mitotic figures scored. This literally allows one to score over 100 crypts (if so wished) and as the results are expressed per crypt the effects of changes in denominator are automatically accounted for.

R A Goodlad

Correspondence to: Dr R A Goodlad, Cancer Research UK, 44 Lincoln’s Inn Fields, London WC2A 3PX, UK; goodlad@cancer.org.uk

Conflict of interest: None declared.

References


Author’s reply

We thank Goodlad for his interest in our article. In our study (Gut 2004;53:1610–16), we assessed expression of Ki67, p53 and geminin in tissue sections. Our main finding was that the number of MCM positive cells can greatly exceed other labels and they are widely distributed on unreplicated chromatin. They would appear to be more of an indicator of replication potential and, as such, are likely to be useful markers of dysplasia.3 In addition, scoring immunohistochemical labelled cells is just as, if not more, “subjective and error prone” than scoring mitotic figures (which are far easier to score in “squash” preparations than in sections). My main

References


Conflict of interest: None declared.

Author’s reply

Further to Cummings and Coleman’s reply to my letter above, I would like to question the advocacy of minichromosome maintenance (MCM) proteins as proliferative markers, as the number of MCM positive cells can greatly exceed other labels and they are widely distributed on unreplicated chromatin. They would appear to be more of an indicator of replication potential and, as such, are likely to be useful markers of dysplasia. In addition, scoring immunohistochemical labelled cells is just as, if not more, “subjective and error prone” than scoring mitotic figures (which are far easier to score in “squash” preparations than in sections). My main
concern still stands, as scoring histological sections of human biopsies, unlike squash preparations, leads to the sampling of a very limited number of crypts (2–4 in the present study) which prevents credence of the “observed lack of effect” of prebiotic carbohydrates.

Finally, I think that the jury is still out on the “protective role” of fermentable non-starch polysaccharides (fibre) as while the EPIC study showed a dramatic effect of intrinsically high fibre diets, many others have shown null effects and some of these, especially the intervention ones, demonstrated adverse effects. For example, wheat bran supplementation increased polyph recurrent in women and ispaghula had a more general adverse effect on polyps.2

R A Goodlad, D Alferez
Cancer Research UK, London, UK
Correspondence to: Dr R A Goodlad, Cancer Research UK, 44 Lincoln’s Inn Fields, London WC2A 3PX, UK; goodlad@cancer.org.uk
Conflict of interest: None declared.

References

Author’s reply
We sought to identify cells at any point of the cell cycle, regardless of the rate of cycling or the duration of particular cell cycle phases. We were not interested to assess individual cell cycle phases in our samples, either by immunostaining or by counting mitotic figures. While additional roles for minichromosome maintenance (MCM) proteins have been suggested, there is strong evidence that they function as essential replication factors.1 MCMs are displaced from chromatin following DNA replication, yet remain abundant in the nucleus throughout the cell cycle.1 Importantly, several groups have shown that MCMs are lost following cell cycle exit (into differentiation, quiescence, or senescence).1,2,3 MCMs are therefore useful immunohistochemical markers of cell cycle state. It is not surprising that MCMs are more abundant than Ki67 and proliferating cell nuclear antigen (PCNA), as the latter markers are not detectable in all cycling cells.

Objectivity and reproducibility in the interpretation of immunohistochemical staining are functions of the marker used. Some markers, such as PCNA, produce substantial variation in staining intensity and cause difficulty in slide interpretation. However, our MCM antibodies have not provided us with such difficulties, resulting in low interobserver variation in numerous studies to date.4

Interpreting observational and intervention studies of fibre has filled many journal pages in recent years. There are numerous problems which, in the context of the present discussion, relate primarily to people treating all sources of fibre as being equal, thinking that fibre supplements will have the same effect as fibre present in whole foods in the diet and the amounts of fibre considered to be protective. With regard to the study by Alberts and colleagues, the fibre was provided as a supplement and was only of wheat bran. As Goodlad and Alferez correctly note, the EPIC study showed a null effect for fibre when intrinsically part of the diet, and from mixed sources. In other words, it is a high fibre diet that protects. The Bonithon-Kopp study1 used a fibre supplement, ispaghula, not found in most of the world, and at a very small dose of only about 3 g/day.

J Cummings
Ninewells Hospital and Medical School, Dundee, UK
Correspondence to: Dr N Coleman, MRC Cancer Cell Unit, Hutchison/MRC Centre, Hills Rd, Cambridge CB2 2XZ, UK; nc109@cam.ac.uk
Conflict of interest: None declared.

References

Recurrentence of exhausting hiccup in a patient treated with chemotherapy for metastatic colon cancer
A 61 year old man was surgically treated for a pT3 N1-G2 MO adenocarcinoma of the colon in February 2003. Immediately after surgery, an enteric fistula occurred that caused a delay in administration of adjuvant treatment. At the start of adjuvant chemotherapy (CT) in May 2003, CEA level was 18.2 ng/ml and a new work-up with computed tomography scan of the thorax and abdomen revealed the early appearance of two metastatic lesions in the liver. The patient underwent liver metastasectomy and in July 2003 was started on post-surgical systemic CT with the FOL-FIRI (leucovorin, 5-fluorouracil, irinotecan) regimen every 14 days for six months. During the second course of CT the patient experienced severe hiccup which was treated with metoclopramide without improvement. Hiccup was ascribed to the use of irinotecan and the patient subsequently received an alternative chemotherapy regimen, prophylactic oral chlorpromazine with significant reduction of the symptom. This approach yielded completion of the CT programme.

In January 2004, relapse of disease occurred in the liver that was not surgically manageable and the patient was started on the FOL-FOX (leucovorin, 5-fluorouracil, oxaliplatin) regimen. After day 1 of CT, recurrence of an exhausting hiccup was observed that continued for nine days after therapy. No benefit from the re-use of chlorpromazine was obtained.

Notably, while undergoing the two CT regimens, the patient had received intravenous ondansetron (8 mg) plus intravenous dexamethasone (8 mg), which was used for prophylaxis of delayed emesis. In order to identify the causative drug of hiccup and taking into consideration previous reports indicating dexamethasone as a possible cause of hiccup,2 during the following cycles of CT this drug was omitted. This approach allowed the patient to continue CT without recurrence of hiccup.

This strong temporal relation between dexamethasone administration and occurrence of hiccup indicated that this drug was the cause of the patient’s hiccup. Moreover, discontinuing dexamethasone was sufficient to achieve disappearance of hiccup without any further pharmacological intervention.

The mechanism of corticosteroid induced hiccup is unknown, although some hypotheses have been proposed.3,4 For example, it has been suggested that there is a hiccup centre in the midbrain that receives input from the thoracic sympathetic nerves and the pharyngeal plexus. It has been proposed that stimulation of the midbrain or these various pathways may be responsible for production of hiccup. Moreover, animal studies suggested that corticosteroids may reduce the synaptic transmission threshold in the midbrain and affect the metabolism of brain neurotransmitters.5,6

We reported our case to make oncologists aware that a symptom appearing during CT treatment (hiccup in our case) should not always be ascribed to the use of antineoplastic drugs. It is also true that some cytotoxic drugs such as irinotecan and cyclophosphamide, have been implicated as a cause of hiccup.7,8 In particular, the incidence of hiccup after treatment with irinotecan was reported in 49/1618 patients and, as for other cytotoxic drugs, almost exclusively in men (49/9313).9

E Errante, D Bernardi, A Bianco
Division of Medical Oncology, Ospedale Civile, Vittorio Veneto (TV), Italy

N Zanatta
Division of Internal Medicine, Ospedale Civile, Vittorio Veneto (TV), Italy

L Salvador
Division of Medical Oncology, Ospedale Civile, Vittorio Veneto (TV), Italy

Correspondence to: Dr E Errante, UO Oncologia, Ospedale Civile, Via Forlonomi 71, 31029 Vittorio Veneto (TV), Italy; domenico.errante@iss.it
doi: 10.1136/gut.2005.071704
Conflict of interest: None declared.
Laterally spreading tumour in which interstitial deletion of β-catenin exon 3 was detected

Laterally spreading tumours (LSTs) of the colon and rectum are defined as lesions greater than 10 mm in diameter with a low vertical axis that extend laterally along the luminal wall. As most LSTs remain as adenomas or early invasive cancers, LSTs have been thought to have relatively little malignant potential. LSTs are divided into two macroscopic subtypes: flat (F)-type, which is composed of superficially spreading lesions with flat and smooth surfaces, and granular (G)-type, which is composed of superficially spreading aggregates of nodules. Despite distinctive biological behaviours of LSTs, only a few genetic alterations have been reported, such as K-ras and p53 mutations and cyclloxygenase 2 overexpression.

A 62 year old Japanese woman was referred to our hospital for treatment of a colonic tumour. Colonoscopy in our hospital showed a F-type LST with a central depression surrounded by a flat elevated area with a smooth surface in the caecum (fig 1A). Microscopically, the tumour consisted of a well differentiated adenocarcinoma with a tubular adenoma and had invaded the submucosal layer.

After obtaining informed consent from the patient, genetic analysis was carried out. No genetic alterations were found in APC, K-ras, or p53 genes. To clarify relevant alterations of gene expression, we analysed the gene expression profiles by a cDNA array. Among 350 cancer related genes, bone morphogenetic protein 4 (BMP4) was one of the most differentially expressed genes in tumour tissues and matched normal tissues (fig 1B). BMP4 is a member of the transforming growth factor β superfamily of growth factors. As BMP4 expression is reportedly correlated with oncogenic β-catenin in human colon cancer cell lines, we analysed alterations in β-catenin in tumour tissues. Intense nuclear expression of β-catenin was immunohistochemically seen within the nuclei of tumour cells (fig 1C).

It would be interesting to investigate the frequency of β-catenin and APC alterations in a number of LST cases.

Microsatellite instability (MSI) due to defective DNA mismatch repair occurs in the majority of hereditary non-polyposis colorectal cancers (HNPCC) and in 10–15% of sporadic colorectal cancers. It has been reported that β-catenin mutations occur more often in MSI positive colorectal cancers. However, tumour tissues in the present case were MSI negative. Samowitz and colleagues reported that β-catenin exon 3 mutations were rare in small (<1 cm) sporadic adenomas (1/83, 1.2%), HNPCC adenomas (1/37, 2.7%), and in both MSI positive (9/34) and MSI negative (9/78) sporadic colorectal cancers. In contrast, a significantly increased frequency (8/44, 18.2%) was found in HNPCC cancers. The...

Figure 1 (A) Endoscopic picture with indigo carmine dye spraying showing an F-type laterally spreading tumour with a central depression surrounded by a flat elevated area in the caecum. (B) cDNA array hybridisation image of the tumour and non-tumour tissues. bone morphogenic protein 4 (BMP4) was one of the most differentially expressed genes in the tumour tissues and matched normal tissues. (C) Intense nuclear expression of β-catenin immunohistochemically seen within the nuclei of tumour cells. (D) Interstitial deletion examined by polymerase chain reaction spanning the genomic region flanking exon 3 and the surrounding introns. A shorter band was detected in both carcinoma and adenoma tissues compared with the normal size of 931 bp. CA, carcinoma tissue; TA, tubular adenoma tissue; N, normal tissue.

Figure 2 DNA sequencing showing interstitial deletion of the 394 bp region in tumor tissue. Three base inverted repeats, AGC and GCT, were found in sequences flanking the interstitial deletion. The deletion included the part of exon 3 containing critical serine and threonine codons for GSK-3β phosphorylation.

References

present patient had no past history or family history of cancer. It would be interesting to investigate whether β-catenin mutation positive HNPCC cancers have any specific morphological features.

K Nosho, H Yamamoto, M Mikami, T Takahashi, Y Adachi, T Endo First Department of Internal Medicine, Sapporo Medical University, Sapporo, Japan

K Hirata First Department of Surgery, Sapporo Medical University, Sapporo, Japan

K Imaizumi, Y Shinozuka First Department of Internal Medicine, Sapporo Medical University, Sapporo, Japan

Correspondence to: Dr K Nosho, First Department of Internal Medicine, Sapporo Medical University, S-1, W-16, Chuo-ku, Sapporo 060-8543, Japan; nosho@sapmed.ac.jp
doi: 10.1136/gut.2005.075184

Conflict of interest: None declared.

References

Functional role of the 503F variant of the organic cation transporter OCTN1 in Crohn’s disease

Several susceptible gene loci were identified as being involved in the aetiology of Crohn’s disease (CD). Recently, a non-synonymous single nucleotide polymorphism in the SLC22A4 gene encoding the organic cation transporter OCTN1 has been linked with CD in Caucasian populations (a 1672CT transversion, resulting in the amino acid substitution L503F). However, the functional consequences of this alteration are unclear as yet.

We have now discovered that L-ergothioneine (ET, 2-mercaptohistidine trimethylbeta-taine), a naturally occurring water soluble thiol compound of dietary origin, is a physiological substrate of OCTN1. Analysis of the concentration dependence of ET transport in Caco-2 transfected HEK293 fibroblasts by liquid chromatography tandem mass spectrometry revealed that the 503F variant was associated with a threefold higher substrate affinity (1/Km) and a two-fold lower maximal transport velocity (Vmax), which resulted in a 50% higher initial transport capacity (Vmax/Km) of OCTN1 at low ET levels (<10 μmol/l) (fig 1A). Analysis of the time course of ET transport showed a higher clearance for the 503F variant (CL (503F) = 1.65 × CL (503L) at an ET concentration of 10 μmol/l) (fig 1B). ET transport by 503L and 503F was sodium independent (fig 1C) and robust to 100 μmol/l sodium reduction (fig 1D).

Figure 1 Ethergothioneine and OCTN1. Concentration dependence, Km, and Vmax of specific ergothioneine (ET) uptake in HEK293 cells constitutively expressing the 503L variant or the 503F variant after one minute of loading (A); specific uptake and clearance (CL) over a time course after incubation with 10 μmol/l ET (B); effects of sodium (C) and pH (D) on specific uptake after one minute of loading with 10 μmol/l ET. In sodium reduced transport buffer, NaCl was isotonically replaced with choline chloride (which did not interfere with ET transport). Resulting formazan formation was determined by absorbance at 568 nm (E).

Table 1 Ethergothioneine uptake by cells transfected with OCTN1 (nmol/mg protein/min)

<table>
<thead>
<tr>
<th>Variant</th>
<th>Km (μmol/l)</th>
<th>Vmax (nmol/mg protein/min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>503L</td>
<td>4.2 (10)</td>
<td>2.5 (1)</td>
</tr>
<tr>
<td>503F</td>
<td>1.4 (10)</td>
<td>1.3 (1)</td>
</tr>
</tbody>
</table>

Table 2 Effect of sodium on ET uptake by Caco-2 transfected cells

<table>
<thead>
<tr>
<th>Variant</th>
<th>CL (nmol/ml/min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>503L</td>
<td>33.1 (4.6)</td>
</tr>
<tr>
<td>503F</td>
<td>54.5 (5.3)</td>
</tr>
</tbody>
</table>

Table 3 Effect of pH on ET uptake by Caco-2 transfected cells

<table>
<thead>
<tr>
<th>Variant</th>
<th>pH</th>
<th>Absorption (568 nm % of control)</th>
</tr>
</thead>
<tbody>
<tr>
<td>503L</td>
<td>5.5</td>
<td>180</td>
</tr>
<tr>
<td>503F</td>
<td>7.5</td>
<td>100</td>
</tr>
</tbody>
</table>

Figure 2 Ergothioneine mRNA expression in Caco-2 cells

Graphs showing the relative expression of OCTN1 mRNA expression (relative to the housekeeping gene GAPDH, lowest expression was set to 1) in Caco-2 cells transfected with OCTN1, ergothioneine, or glutathione (E).

Graphs showing the relative expression of OCTN1 mRNA expression (relative to the housekeeping gene GAPDH, lowest expression was set to 1) in Caco-2 cells transfected with OCTN1, ergothioneine, or glutathione (E).

Graphs showing the relative expression of OCTN1 mRNA expression (relative to the housekeeping gene GAPDH, lowest expression was set to 1) in Caco-2 cells transfected with OCTN1, ergothioneine, or glutathione (E).
and pH dependent; only at unphysiologically low Na+ and pH values were the differences in transport activity between both variants lost (IC50). Considering that maximal levels of ET found in tissues and in common foods are in the nanomolar to low micromolar range, our data suggest that carriers of the 503F allele accumulate higher ET concentrations in OCTN1 expressing cells compared with carriers of the wild-type 503L allele. Therefore, high tissue levels of ET may constitute a possible risk factor for CD.

The involvement of OCTN1 in the inflammatory process is further supported by observations that OCTN1 is strongly expressed in intestinal epithelial and immunological cells, particularly in CD4+ monocytes/macrophages playing a key role in the immunopathogenesis of CD, as well as by the finding that levels of SLC22A4 mRNA were upregulated by proinflammatory cytokines such as tumour necrosis factor α. Moreover, we found transcriptional regulation of SLC22A4 to determine essentially ET uptake: in CD4+ monocytes homozygous for the 503L variant, expression levels of SLC22A4 mRNA showed high interindividual heterogeneity and were directly proportional to cellular ET content (fig 1B). Accordingly, in CD4+ and CD8+ lymphocytes lacking OCTN1 expression, we detected no ET (data not shown).

The physiological or pathophysiological functions of ET are as yet unknown. We tested the effect of ET on proliferation of the colon cancer epithelial cell line Caco-2 that was shown to be homozygous for the susceptible 503F allele and to express high levels of OCTN1 mRNA. Cell proliferation was enhanced in a dose dependent manner after exposure to ET concentrations above 20 μmol/l for 24 hours: at 200 μmol/l, proliferation was increased to 120 (3%) of the buffer control and intracellular ET concentration reached 6.7 (0.3) nmol/mg protein. In contrast, no stimulation of proliferation was seen when a Caco-2 variant without OCTN1 expression was employed; consequently, after treatment with 200 μmol/l ET, only diffusion controlled uptake to 0.67 (0.03) nmol/mg protein occurred. When incubated with glutathione, both Caco-2 cell lines exhibited an antioxidant typical inhibition of proliferation that was independent of OCTN1 expression (fig 1C). OCTN1, rather than antioxidant activities, stimulatory effects on cell proliferation appear to constitute the functional role of ET. ET may accelerate the inflammation process by transcriptional activation of fibroblast repair proliferation, thereby also conferring susceptibility of CD patients to develop colorectal cancer.

Collectively, our data suggest that the OCTN1 substrate ET is a proliferative factor in diseases such as CD, and subjects carrying the 503F allele are at an increased risk due to a higher intracellular accumulation of ET.

D Taubert, G Grimberg* Department of Pharmacology, Medical Hospital of the University of Cologne, Cologne, Germany

N Jung, A Rubbert Department of Internal Medicine I, Medical Hospital of the University of Cologne, Cologne, Germany

E Schöning Department of Pharmacology, Medical Hospital of the University of Cologne, Cologne, Germany

Correspondence to: Dr D Taubert, Department of Pharmacology, Medical Hospital of the University of Cologne, Gleueler Str 24, D-50931 Cologne, Germany; dirk.taubert@medizin.uni-koeln.de

doi:10.1136/gut.2005.076083

*D Taubert and G Grimberg contributed equally to the study.

Conflict of interest: None declared.

References


Diarrhoea as a presentation of bird flu infection: a summary on its correlation to outcome in Thai cases

Bird flu or avian flu, caused by H5N1 virus, is a new emerging infectious disease. There has been worldwide avian influenza infections in poultry since 1997. Recently, H5N1 caused severe disease with high mortality in humans in Vietnam and Thailand.1 Most infected cases usually developed progressive pneumaonia with acute respiratory distress syndrome and consequently died. Atpypical presentations of patients with bird flu were also noted. de Jong et al recently reported a fatal bird flu infected case in Vietnam with a presentation of diarrhoea, without respiratory symptoms.1

I performed a mini-study in order to document the magnitude of diarrhoeal presentation among reported Thai patients and the correlation with outcome. A literature review on papers concerning human bird flu in Thailand was performed using databases of published works cited in Index Medicus and the Science Citation Index. I also reviewed published reports in 256 local Thai journals, which are not included in the international citation index, for reports of human bird flu infection in Thailand. Studies that contained incomplete data were excluded from further analysis.

Six reports1–6 of 12 Thai patients with a confirmed diagnosis of bird flu were found. Of 12 infected cases, respiratory symptoms were seen in all cases and diarrhoea was detected at presentation in five cases (41.7%). Considering the five diarrhoeal cases, acute diarrhoea is as frequent as acute respiratory distress syndrome, with a mortality rate of 20% (p = 0.05) or fatality (p = 0.05) but there was a significant correlation between the development of ARDS and fatality (p = 0.001).

There are some reports of diarrhoea in severe bird flu infection. Poovorawan recently proposed that diarrhoea was an important presentation of bird flu and could imply a poor prognosis.2 Here, I attempted to assess the magnitude of diarrhoea among Thai infected cases and its correlation with infection outcome. According to this study, the prevalence of diarrhoeal presentation was high, similar to a recent study in Vietnam (approximately 70%).3 I therefore conclude that diarrhoeal presentation had a poor correlation with outcome in our subjects.

V Wiwanitkit

Correspondence to: Dr V Wiwanitkit, Department of Laboratory Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand 10330; wviroj@yahoo.com

doi:10.1136/gut.2005.072488

Conflict of interest: None declared.

References


High levels of disease related prion protein in the ileum in variant Creutzfeldt-Jakob disease

Disease related prion protein (PrPSc) is readily detectable in lymphoreticular tissues in variant Creutzfeldt-Jakob disease (vCJD) but not in other forms of human prion disease. This distinctive pathogenesis together with the unknown population prevalence of asymptomatic vCJD infection1–3 has led to significant
concerns that secondary transmission of vCJD prions will occur through a wide range of surgical procedures. Risk assessment for intestinal endoscopy, biopsy, and surgery is currently limited by a lack of knowledge about relative PrPSc levels and prion titres within intestinal tissues in vCJD patients. Because of its high content of lymphoid follicles, terminal ileum is regarded as the intestinal tissue having the highest potential for iatrogenic transmission of vCJD prions. Here we provide the first report of relative PrPSc concentrations in vCJD terminal ileum.

Tissues were obtained at autopsy with consent from relatives from four patients with neuropathologically confirmed vCJD and two patients with neuropathologically confirmed sporadic CJD (both PRNP codon 129MM with type 2 PrPSc in brain). Terminal ileum was analysed for PrPSc by high sensitivity immunoblotting and for abnormal PrP immunoreactivity by immunohistochemistry. Using these methods, terminal ileum from all four vCJD cases showed high levels of detectable PrPSc (fig 1A). In three vCJD cases, 2/2 homogenates prepared from each ileum sample were positive for PrPSc whereas 2/4 ileum homogenates were positive in the other vCJD case. The glycoform ratio of protease resistant fragments of di-, mono-, and non-glycosylated PrP in terminal ileum appeared to be closely similar to the type 4t PrPSc pattern seen in vCJD tonsil. Although there was variation in PrPSc concentration between different homogenates of vCJD terminal ileum, PrPSc levels in positive samples were typically in the range 0.1–1% of that present in vCJD brain (fig 1B). With respect to both sampling variation and PrPSc concentration, terminal ileum appears to be closely similar to lymph nodes in vCJD. These findings, together with our previous studies, show that PrPSc deposition within the intestine is not uniform in vCJD. From the four cases of vCJD with PrPSc positive terminal ileum studied here, 0/2 cases with available tissue had detectable PrPSc in the appendix and only 1/3 cases had detectable PrPSc in the rectum. In contrast with findings with vCJD terminal ileum, no detectable PrPSc was found in homogenates of terminal ileum prepared from sporadic CJD patients (fig 1A). The lack of detection of PrPSc in sporadic CJD terminal ileum extends our previous findings for one of these cases in which we have previously reported a lack of detectable PrPSc in tonsil, rectum, and appendix.

In agreement with findings from immunoblotting, immunohistochemistry showed abnormal PrP deposition in the terminal ileum in vCJD (fig 1C) but not in sporadic CJD (data not shown). The irregular distribution of abnormal PrP positive lymphoid follicles seen in vCJD terminal ileum is consistent with variation in PrPSc concentration detected in different terminal ileum samples by immunoblotting. Although from necessarily limited numbers investigated, the uniform presence of PrPSc in vCJD terminal ileum, at concentrations of up to 1% of those found in vCJD brain, reinforces concerns that iatrogenic transmission of vCJD prions might occur through contaminated intestinal endoscopes, biopsy forceps, or surgical instruments. These findings should assist policy makers in the UK and elsewhere in risk assessments about the use of disposable forceps for intestinal biopsy. Alternative approaches to risk reduction may now be possible as practical means of prion decontamination for endoscopes and surgical instruments are now feasible using enzymatic methods.

Acknowledgements
This study was funded by the UK Medical Research Council and was performed under the approval of the Institute of Neurology/National Hospital for Neurology and Neurosurgery Local Research Ethics Committee.

Conflict of interest: declared (the declaration can be viewed on the Gut website at http://www.gutjnl.com/supplemental)

S Joiner, J M Linehan, S Brandner, J D F Wadsworth, J Collinge
MRC Prion Unit and Department of Neurodegenerative Disease, Institute of Neurology, University College London, National Hospital for Neurology and Neurosurgery, London, UK
Correspondence to: Professor J Collinge, MRC Prion Unit and Department of Neurodegenerative Disease, Institute of Neurology, University College London, National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK; j.collinge@prion.ucl.ac.uk

doi: 10.1136/gut.2005.072447

References
3 Wadsworth JBF, Joiner S, Hill AF, et al. Tissue distribution of protease resistant prion protein in variant CJD using a highly sensitive

www.gutjnl.com

Figure 1 (A, B) High sensitivity immunoblots using anti-prion protein (PrP) monoclonal antibody 3F4. (A) Proteinase K digested sodium phosphotungstic acid pellets from 0.5 ml of 10% terminal ileum homogenates from variant Creutzfeldt-Jakob disease (vCJD) patients 1–4 or sporadic CJD (sCJD) patients 1 and 2. (B) Proteinase K digested sodium phosphotungstic acid pellets from 0.5 ml of 10% normal human tonsil homogenerate (normal tonsil) or 0.5 ml of 10% normal human tonsil homogenate spiked with 2.5 μl of 10% brain homogenate from vCJD patient No 4 (spiked tonsil) were compared with a proteinase K digested sodium phosphotungstic acid pellet from 0.5 ml of 10% terminal ileum homogenate from the same vCJD patient. (C) Photomicrograph showing abnormal PrP immunoreactivity in a lymphoid follicle in vCJD terminal ileum (anti-PrP monoclonal antibody ICSM 35). Scale bar, 100 μm. Inset, high power magnification of PrP deposits.


**Chronic inflammatory intestinal diseases and bone loss**

We were very interested in the recent article by Moschen et al on activation of the RANKL/OPG system in inflammatory bowel disease (IBD) (Gut 2005; 54:479–87). Until recently, osteoporosis secondary to gastrointestinal diseases was mainly considered a direct consequence of malabsorption. The article of Moschen et al and a previous one of our group on bone loss in coeliac disease, a disorder similarly characterised by intestinal inflammation, offer a new perspective on the consequence of malabsorption.

The article of Moschen et al, which is the first one of our group on bone loss in coeliac disease, a disorder similarly characterised by intestinal inflammation, offers a new perspective on the consequences of malabsorption. The authors do provide a list of suggested readings for further introduction to the scientific literature.

The information is generally presented in a refreshing and amicable style. I think the book is friendly enough to be of benefit to an average student, but at the same time it caters adequately for the more seasoned learner too. It features some beautiful pictures and drawings depicting many individuals who have contributed to this field over the last hundred or so years. I thought the cartoons in the chapter on Helicobacter pylori were particularly pleasing and informative.

I particularly liked the background to the development of the first proton pump inhibitor (PPI). I thought this was thought-provoking and will no doubt enable me to create a greater impression in front of the next PPI rep that I meet. The chapter on peptic ulcer disease is by and large pari for the course, but the section on Barrett’s oesophagus presents a very logical and sensible approach towards tackling an area which remains controversial.

As a matter of personal taste, I would like to have seen a few key messages or take home points at the end of each chapter. These can also act as a quick source of reference for those who find that spare time is generally an elusive commodity, which, I suspect, is nearly all of us.

All in all, it is a timely and a creditable addition covering a very important and rapidly evolving field of gastroenterology and the authors ought to be congratulated for their efforts. Would I buy it? Probably yes, but only if I did not have a copy of the first edition. I would certainly recommend it as a departmental book as, among its many virtues, it provides useful tibbits to amuse the audience during presentations.

A Mahmood
High levels of disease related prion protein in the ileum in variant Creutzfeldt-Jakob disease

S Joiner, J M Linehan, S Brandner, J D F Wadsworth and J Collinge

_Gut_ 2005 54: 1506-1508
doi: 10.1136/gut.2005.072447

Updated information and services can be found at:
http://gut.bmj.com/content/54/10/1506.2

These include:

**Supplementary Material**

Supplementary material can be found at:
http://gut.bmj.com/content/suppl/2005/09/09/54.10.1506-a.DC1

**References**

This article cites 11 articles, 2 of which you can access for free at:
http://gut.bmj.com/content/54/10/1506.2#BIBL

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/